GlassScriptPhysician profile
Christopher Garcia
NPI 1295771012
$2,193.43
in general payments reported to CMS, 2019-2025
11 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $275 · 2023: $331 · 2024: $189 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958 · Education: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.84 |
| Education | $709.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,400.17 | 2021-2025 | Wegovy, Ozempic |
| Smith+Nephew, INC. | $240.19 | 2021-2025 | Grafix Pl, Stravix, Oasis |
| Vertex Pharmaceuticals Incorporated | $123.50 | 2025 | Journavx |
| Sanara Medtech INC. | $96.16 | 2024 | Celleraterx |
| Endo Pharmaceuticals INC. | $78.45 | 2021-2023 | Nascobal |
| Lilly USA, LLC | $72.53 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Ethicon US, LLC | $66.43 | 2025 | Endopath Xcel, Linx Reflux Management System |
| Supernus Pharmaceuticals, INC. | $43.20 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $25.39 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.21 | 2021 | |
| Axonics, INC. | $22.20 | 2023 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.